Elevation of ventricular fibrillatory threshold by beta-adrenergic blocking agents.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000526:Alprenolol / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use; D002040:Levobunolol / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D013015:Sotalol / Q000494:pharmacology / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D004983:Ethanolamines; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D002040:Levobunolol